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Dr William J. Quinones-Baldrich (Los Angeles, Calif). I
congratulate Dr Riley and her co-investigators for their pioneer
work toward the development of a total endovascular solution for
treatment of patients with thoracoabdominal aortic aneurysms.
This is a unique series of 81 patients treated in a relatively stan-
dardized fashion with an endovascular branched graft with cuffs
placed above the origin of the visceral arteries and completed with
covered stents for revascularization of the celiac superior mesen-
teric and renal branches. Approximately 60% of the devices were
custom-made and the remainder had a consistent cuff position
considered a “standard” device. Overall, operative mortality was
6.2%, which is similar to mortality associated with open thoraco-
abdominal aneurysm repair. Cumulative survival, however, was
70% at 2 years and only 50% at 4 years, which leads to my first
question: Considering that almost 40% of patients required some
type of reintervention within the first year, was there any difference
between the cumulative survival of patients requiring reinterven-
tion versus those that did not? We all tend to minimize the impact
of additional interventions in this often elderly group of patients
and therefore I believe it is important to understand the potential
impact of additional procedures.
Approximately half of the patients were type IV thoracoab-
dominal or pararenal aneurysms and the remainder were type II,
III or V. There was an incidence of spinal cord ischemia in the
entire series of 24% with permanent paraplegia occurring in three
patients. How many patients with type IV or pararenal aneurysms
developed spinal cord ischemia? Most of these events occurred
within 24 hours of the procedure with only two occurring late, at
two or three weeks of discharge. Neurologic function improved in
most of these patients with appropriate treatment using cerebro-f them? Do any of them require an assistive device? I noticed that
our protocol for spinal fluid drainage is to drain 10cc/hr. Many of
s prefer to monitor pressure regardless of the amount of fluid
rained, maintaining an intraspinal pressure of 10 cm/H20. After
ll, it is the intraspinal pressure that we are trying to control to
romote spinal cord blood flow.Do you think this may have had an
nfluence on this high incidence of spinal cord ischemia? Have you
ade any changes to reduce this relatively high incidence of spinal
ord ischemia?
Branch graft patency overall was excellent. There was, how-
ver, a significant incidence of renal dysfunction with approxi-
ately 8% of the entire series requiring permanent dialysis. Some of
hese were associated with branch occlusion, although in others
he grafts remain patent. In your conclusions, you expressed the
eed for further technological improvements for renal branch
rafts. Can you share with us those improvements that you think
re needed? I have to assume that these patients were selected from
larger cohort evaluated at your institution for treatment of
horacoabdominal aortic pathology. How many patients were
urned down for this procedure and how were they treated? What
s your current selection criterion for endovascular treatment of a
horacoabdominal aneurysm?
Finally, it is important to recognize that this is an evolving
echnology. The UCSF group and others have been working on
he development of an endovascular graft for repair of thoracoab-
ominal aneurysms for several years. This is an enormous invest-
ent in time and money and any company involved in this effort
ill try to recover their investment. The number of patients for
hich this technology will be applicable is certainly much smaller
han those with abdominal aortic aneurysms. In the current envi-
onment, most hospitals barely cover the cost associated with
ndovascular abdominal aortic aneurysm repair due to device cost.
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July 201264 Reilly et alFrom an economic standpoint, could you speculate as to the
financial impact that the commercial availability of a branched or
fenestrated graft will have in the cost of caring for patients with
thoracoabdominal aortic pathology? Can we afford this?
Once again, I congratulate you and your group for the excel-
lent contributions that you have made and continue to make in
endovascular technology. I thank you for providing me a copy of
the manuscript and your presentation well in advance of the
meeting. I thank the Society for the opportunity to discuss this
important study.
Dr Linda M. Reilly. Thank you, Dr Quinones, for the
opportunity your questions provide to present yet another paper.
The cumulative survival of patients who required reintervention
(71.9%) was the same as the cumulative survival of patients who did
not require reintervention (71.4%). We attribute this apparent lack of
impact of reintervention to the fact that 60% of these reinterventions
were endovascular procedures and an additional 15% involved only
involved treatment of an access site problem.
The three patients with permanent paralysis had one pararenal
aneurysm, one Crawford type II, and one type III aneurysm. The
distribution of aneurysm type among the 16 patients who devel-
oped transient symptoms of spinal cord ischemia was Crawford
type II in five, type III in one, type IV in four, type V in one, and
pararenal in five. The overall rate and impact of breakdown by
aneurysm type makes it impossible to establish or refute any
correlation. Recovery to independent ambulation occurred in all of
these 16. When we began this study, we monitored CSF pressure
and drained CSF fluid to maintain a target CSF pressure. As we
accumulated experience, we concluded that it made more sense to
drain CSF to reach an effect rather than to reach an arbitrarily
determined measurement. We cannot exclude the possibility that
draining CSF at a higher rate might have reduced the incidence of
the transient SCI symptoms.We do not really have the ideal devices for the renal arteries.
These arteries are smaller, more tortuous and more mobile than
p
fhe visceral branches, making cannulation, branch insertion, de-
loyment, and durability a greater challenge. We think that ad-
ances in wires, sheaths, and covered stents specific to these aspects
f renal artery anatomy might help reduce the rate of insertion
njury and late branch failure.
It is difficult to establish an accurate denominator of those
valuated for this procedure.We did eliminate 29 screened patients
n the basis of anatomy, most often involving the access arteries
too small with no option to construct a conduit), the renal arteries
too small or multiple), or the visceral arteries (aneurysmal or early
ritical branches). I cannot tell you how these excluded patients
ere treated, since many of them return to their referring surgeons
or treatment, or in many cases, continued monitoring without
ntervention. We believe that our results support endovascular
AAA/PRAA repair for any patient who is an anatomic candidate;
owever, since we are still treating patients as part of the study,
nrolled patients must still meet the published inclusion criteria for
he study.
The question of whether or not we, that is society, can afford
his type of treatment is important. At the moment, the branched
ortic component is provided at the same cost as a standard
nfrarenal aortic device, but it is unlikely to remain that way when
hese devices are on the market. The cost of each branch and its
ining stent is additional. The amount of time spent in an intensive
are setting is less than with open TAAA repair as the overall length
f stay. As is common with other endovascular techniques, the
educed cost of care will not offset the increased cost of the devices.
ut, I suspect that most open TAAA operations also lose money.
o the question is really broader: does society want to pay for the
reatment of thoracoabdominal aortic aneurysms, and if so, how
uch loss is reasonable? An important part of the answer to that
uestion may be the rapidity of recovery and the quality of life the
atient achieves after treatment, which is really what one is buying
or the cost.
